Arcutis Biotherapeutics, Inc. revenue
Arcutis Biotherapeutics, Inc.'s revenue was $376m in fiscal 2025, up 91.3% on the year before. Since fiscal 2022 ($3.7m) it has grown at a compound 367.3% a year. Over the last twelve months it was $464m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| ZORYVE Foam | $182M | 48.9% | ▲ 154.3% |
| ZORYVE Cream0.3 | $121M | 32.5% | ▲ 42.2% |
| ZORYVE Cream0.15 | $68.3M | 18.3% | ▲ 588.2% |
| ZORYVE Cream0.05 | $911,000 | 0.2% | — |
From Arcutis Biotherapeutics, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. | $464m | 76.1% | 241.4% |
| Cormedix Inc. | $462m | 280.5% | 1135.4% |
| Krystal Biotech, Inc. | $470m | 26.0% | 280.1% |
| Ardelyx, Inc. | $451m | 16.8% | 75.9% |
| Adma Biologics, Inc. | $512m | 8.0% | 35.0% |
| Novavax Inc | $414m | -61.6% | -36.3% |
Compare with peers
- Cormedix Inc. revenue
- Krystal Biotech, Inc. revenue
- Ardelyx, Inc. revenue
- Adma Biologics, Inc. revenue
- Novavax Inc revenue
Head to head: ARQT vs CRMDARQT vs KRYSARDX vs ARQTADMA vs ARQT
More: Biotechnology stocks compared, Health Care sector, rankings of US companies